Chipscreen Biosciences, Ltd.

This early-phase study tests a new drug, CS08399, in people with advanced solid tumors or lymphoma that have a specific gene deletion (MTAP). The main goal is to find a safe dose and understand how the drug works in the body. About 186 participants will take part, and researchers…

This study looks at adding a drug called Chiglitazar to standard SGLT-2 inhibitor treatment for adults with type 2 diabetes whose blood sugar is not well controlled. Researchers will track changes in blood sugar, heart, kidney, and liver health over time. About 3550 participants …

This Phase III trial is testing whether adding the experimental drug chiauranib and an immunotherapy (toripalimab) to standard chemotherapy can help people with metastatic pancreatic cancer live longer. About 558 participants will be randomly assigned to receive either the full c…

This study tests whether a new single pill that combines two diabetes drugs (chiglitazar and metformin) works the same as taking them separately. It involves 64 healthy adults who will take both versions and have their blood levels measured. The goal is to see if the combo pill i…

This early-phase trial in 28 healthy Chinese adults tests a new fixed-dose combination pill for type 2 diabetes. One part checks whether a high-fat meal changes how much drug gets into the blood. The other part looks at drug levels after taking the pill daily for 10 days. The goa…

This pilot study will test whether a new fixed-dose combination tablet containing Chiglitazar and Metformin works the same in the body as taking the two drugs separately. Twenty-four healthy adults will receive both versions under fed conditions, and researchers will measure drug…